NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
24.12
-0.07 (-0.29%)
At close: Sep 15, 2025, 4:00 PM EDT
24.12
0.00 (0.00%)
After-hours: Sep 15, 2025, 4:39 PM EDT
NAMS Revenue
NewAmsterdam Pharma Company had revenue of $19.15M in the quarter ending June 30, 2025, with 740.06% growth. This brings the company's revenue in the last twelve months to $64.01M, up 762.15% year-over-year. In the year 2024, NewAmsterdam Pharma Company had annual revenue of $45.56M with 223.37% growth.
Revenue (ttm)
$64.01M
Revenue Growth
+762.15%
P/S Ratio
40.52
Revenue / Employee
$941,265
Employees
68
Market Cap
2.72B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 45.56M | 31.47M | 223.37% |
Dec 31, 2023 | 14.09M | -88.60M | -86.28% |
Dec 31, 2022 | 102.69M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
NAMS News
- 11 days ago - NewAmsterdam Pharma Company N.V. (NAMS) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 21 days ago - NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September - GlobeNewsWire
- 25 days ago - Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site - PRNewsWire
- 4 weeks ago - NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib - GlobeNewsWire
- 5 weeks ago - NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results - GlobeNewsWire
- 6 weeks ago - NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025 - GlobeNewsWire
- 7 weeks ago - NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025 - GlobeNewsWire
- 3 months ago - NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial - GlobeNewsWire